What type of study is this?

This is a Network Meta-analysis study (also classified as: RCT).

September 10, 2025Frontiers in Cardiovascular MedicineOpen Access

Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

XLXiaoyu LiuShanghai Ninth People's Hospital RDRan DingNorth China University of Science and Technology AZAihua ZhangQingdao University

Discussion

Member takes

Implication

Network meta-analysis reveals Spironolactone and Dexrazoxane are effective against cardiotoxicity in patients, suggesting better treatment strategies.

Key Points

Spironolactone significantly improved left ventricular ejection fraction, enhancing cardiac function during chemotherapy.
Of the 28 randomized controlled trials analyzed, Dexrazoxane reduced the occurrence of cardiac events by 72%.
A comprehensive network meta-analysis was performed, evaluating several therapies aimed at reducing chemotherapy-induced cardiotoxicity.
These findings support the inclusion of cardioprotective agents in treatment regimens to minimize heart-related side effects.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c187209b7b07f3a0610eb2 https://doi.org/10.3389/fcvm.2025.1612060

View Full Paper

Ask AI

Bookmark

Implication

Network meta-analysis reveals Spironolactone and Dexrazoxane are effective against cardiotoxicity in patients, suggesting better treatment strategies.

Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider